Barclays Forecasts Strong Price Appreciation for LifeStance Health Group (NASDAQ:LFST) Stock

by · The Markets Daily

LifeStance Health Group (NASDAQ:LFST – Get Free Report) had its target price boosted by equities research analysts at Barclays from $9.00 to $13.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Barclays‘s target price indicates a potential upside of 19.49% from the stock’s current price.

LFST has been the topic of several other reports. The Goldman Sachs Group started coverage on LifeStance Health Group in a report on Friday, June 5th. They set a “neutral” rating and a $9.00 price target on the stock. KeyCorp raised their price objective on shares of LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Monday. BTIG Research lifted their target price on shares of LifeStance Health Group from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Wall Street Zen upgraded shares of LifeStance Health Group from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 4th. Finally, Zacks Research upgraded LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a report on Monday, April 27th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, LifeStance Health Group presently has an average rating of “Moderate Buy” and a consensus target price of $10.75.

Get Our Latest Analysis on LFST

LifeStance Health Group Trading Up 1.7%

NASDAQ LFST opened at $10.88 on Tuesday. The company has a market cap of $4.22 billion, a price-to-earnings ratio of 181.33 and a beta of 1.12. LifeStance Health Group has a twelve month low of $3.74 and a twelve month high of $11.62. The company has a quick ratio of 1.48, a current ratio of 1.48 and a debt-to-equity ratio of 0.18. The business’s fifty day moving average is $8.74 and its 200 day moving average is $7.56.

LifeStance Health Group (NASDAQ:LFST – Get Free Report) last issued its earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The business had revenue of $403.48 million during the quarter, compared to analysts’ expectations of $387.46 million. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The business’s revenue was up 21.2% on a year-over-year basis. As a group, sell-side analysts expect that LifeStance Health Group will post 0.12 EPS for the current fiscal year.

Insider Activity

In other news, Director Robert Bessler sold 894,337 shares of the company’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $10.13, for a total value of $9,059,633.81. Following the completion of the transaction, the director directly owned 539,763 shares of the company’s stock, valued at $5,467,799.19. This represents a 62.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Eric Shuey sold 243,362 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $8.02, for a total value of $1,951,763.24. Following the completion of the transaction, the director owned 867,562 shares of the company’s stock, valued at $6,957,847.24. This trade represents a 21.91% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 7,762,394 shares of company stock valued at $64,107,859 over the last three months. Corporate insiders own 3.50% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. boosted its holdings in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock worth $60,000 after buying an additional 1,367 shares during the period. Park Edge Advisors LLC grew its holdings in LifeStance Health Group by 14.4% during the 4th quarter. Park Edge Advisors LLC now owns 11,863 shares of the company’s stock valued at $84,000 after buying an additional 1,495 shares in the last quarter. California State Teachers Retirement System increased its position in shares of LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after buying an additional 1,966 shares during the period. Vident Advisory LLC increased its position in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after buying an additional 2,447 shares during the period. Finally, Xponance LLC lifted its holdings in shares of LifeStance Health Group by 26.4% in the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock worth $93,000 after buying an additional 2,745 shares in the last quarter. 85.50% of the stock is currently owned by institutional investors.

About LifeStance Health Group

(Get Free Report)

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.

See Also